Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) EBIT : $0.99 Mil (TTM As of Mar. 2017)

View and export this data going back to 2001. Start your Free Trial

What is Aoxing Pharmaceutical Co EBIT?

Aoxing Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2017 was $0.88 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2017 was $0.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aoxing Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2017 was 3.06%. Aoxing Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was 10.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aoxing Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was 68.74%.

Aoxing Pharmaceutical Co EBIT Historical Data

The historical data trend for Aoxing Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aoxing Pharmaceutical Co EBIT Chart

Aoxing Pharmaceutical Co Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Jun16

EBIT

Get a 7-Day Free Trial

-1.15

-6.55

-3.34

8.70

6.23

Aoxing Pharmaceutical Co Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EBIT	Get a 7-Day Free Trial															1.53	-1.85	1.70	0.25	0.88

Competitive Comparison of Aoxing Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Aoxing Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aoxing Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aoxing Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aoxing Pharmaceutical Co's EV-to-EBIT falls into.

Aoxing Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.99 Mil.

Aoxing Pharmaceutical Co (OTCPK:AOXG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aoxing Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2017 is calculated as:

	ROC % (Q: Mar. 2017 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2016 )	+	Invested Capital (Q: Mar. 2017 ))	/ count )
=	3.512 * ( 1 - 51.85% )	/	( (53.675	+	56.844)	/ 2 )
=	1.691028	/	55.2595
=	3.06 %

where

	Invested Capital		(Q: Dec. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	58.724	-	14.721	-	( 6.849	-	max(0, 40.511	-	30.839	+	6.849	))
=	53.675

	Invested Capital		(Q: Mar. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	62.466	-	14.79	-	( 7.08	-	max(0, 43.971	-	34.803	+	7.08	))
=	56.844

Note: The Operating Income data used here is four times the quarterly (Mar. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Aoxing Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2017 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2017 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2016		Q: Mar. 2017
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	3.512	/	( ( (24.066 + max(6.976, 0))	+	(24.04 + max(10.593, 0)) )	/	2 )
=	3.512	/	( ( 31.042	+	34.633 )	/	2 )
=	3.512	/	32.8375
=	10.70 %

where Working Capital is:

	Working Capital		(Q: Dec. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(12.846	+	2.044	+	8.308)	-	(14.721	+	0.335	+	1.166)
=	6.976

	Working Capital		(Q: Mar. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(14.505	+	2.406	+	10.03)	-	(14.79	+	0.262	+	1.296)
=	10.593

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2017) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aoxing Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2017 )
	=	0.985	/	1.433
	=	68.74 %

Aoxing Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Aoxing Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aoxing Pharmaceutical Co Inc (OTCPK:AOXG) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

624 Tyvola Road, Suite 103, No. 186, Charlotte, NC, USA, 28217

Website

http://www.aoxingpharma.com

Aoxing Pharmaceutical Co Inc is a specialty pharmaceutical company. The company specializes in research, development, manufacturing, and distribution of a variety of narcotic, pain-management, and addiction treatment pharmaceutical products. Aoxing holds approximately 139 drug production certificates covering narcotic pain-management, exclusive prescription medicines, OTC and API products. It derives all its revenue from the People's Republic of China.

Executives

Wilfred Chow	officer: Chief Financial Officer	30 WEST STREET, 3B, NEW YORK NY 10004
John P Oshea	director	C/O WESTMINSTER SECURITIES CORP, 100 WALL ST, 7TH FLOOR, NEW YORK NY 10005
John Leo	director, officer: Secretary	80 WALL STREET, 5TH FLOOR, NEW YORK NY 10005

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Headlines

No Headlines